Overview HL-085 in NRAS-mutated Advanced Melanoma Status: Recruiting Trial end date: 2022-11-20 Target enrollment: Participant gender: Summary This was an open-label, single-arm, multi-center phase II clinical study, aimed at investigating the efficacy and safety of HL-085 capsule in the treatment of advanced melanoma patients with NRAS mutation. Phase: Phase 2 Details Lead Sponsor: Shanghai Kechow Pharma, Inc.